However, applying KAPAC to five normal and five glioblastoma tumor samples which showed most separable distributions of terminal exon lengths, we uncovered a pyrimidine motif, likely bound by PTBP1, as most significantly associated with changes in PAS use in these tumors. Here, PTBP1 is linked to glioblastoma.